Verastem Inc

VSTM remains in a pronounced Stage 4 decline with clear lower highs and lower lows, trading below all major EMAs. The recent bounce into the 9/21 EMA zone was rejected, and despite RSI recovering from oversold, there is no reversal signal. Execution should be deferred, focusing on trimming into rallies toward the declining EMA region to preserve downside exposure.

• ↑Q1 2026 net product revenue at $18.7M, marking sustained growth
• ↑Phase 1/2 VS-7375 shows preliminary anti-tumor efficacy in KRAS G12D patients
• ↓Q1 non-GAAP net loss of $42.7M ($0.43/sh) underscores low profitability